Metroderme

Metronidazole, the active ingredient in Metroderme, is a nitroimidazole antibiotic presented as a topical formulation for topical use. It treats anaerobic bacterial and protozoal skin infections in adults and children. The product meets EU quality standards and is manufactured under GMP conditions. It is intended for external application on affected skin areas. Healthcare professionals select Metroderme for its targeted antimicrobial activity and favorable tolerability profile.

GNH USA supplies Metroderme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole is used topically to manage infections caused by anaerobic bacteria and certain protozoa.

- Rosacea: reduces inflammatory papules, pustules and persistent erythema. - Bacterial vaginosis: eradicates anaerobic bacterial overgrowth in the vaginal flora. - Perioral dermatitis: controls the bacterial component and improves skin appearance.

Topical application of Metroderme may cause local reactions, while systemic absorption can rarely produce serious events.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site. - Burning or stinging sensation during or after use. - Dryness or peeling of the treated skin. - Itching or mild pruritus. - Erythema: transient redness. - Sensation of warmth.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe skin rash or bullous dermatitis. - Photosensitivity leading to exaggerated sunburn. - Anaphylaxis: rapid onset of systemic allergic response. - Systemic toxicity: nausea, headache, or seizures (rare with extensive use).

When using Metroderme, consider the following safety measures.

- Hypersensitivity: avoid if the patient has known allergy to metronidazole or nitroimidazoles. - Extensive skin damage: do not apply on large open wounds, burns, or ulcerated areas. - Pregnancy and lactation: use only if the prescriber determines benefit outweighs risk. - Alcohol consumption: advise patients to limit alcohol to reduce disulfiram‑like reactions. - Concomitant medications: review for potential interactions before initiating therapy. - Store at room temperature: keep in the original container, protect from moisture and light.

Metronidazole can interact with several systemic agents; monitoring is advised.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, nausea, and tachycardia. - Warfarin: increased anticoagulant effect, risk of bleeding. - Lithium: heightened lithium toxicity. - Phenytoin: reduced efficacy of metronidazole. - Cimetidine: elevated metronidazole plasma concentrations.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive effectiveness. - Other antiepileptics (e.g., carbamazepine): enzyme induction may lower metronidazole levels. - Rifampin: may decrease metronidazole exposure, reducing therapeutic effect.